… records from patients with advanced LSQC treated with erlotinib … lung cancer patients who
had histological or cytological diagnosis of squamous cell carcinoma, had history of erlotinib …

… resistance to erlotinib in patients with lung adenocarcinoma. To … and erlotinib in patients
with acquired resistance to erlotinib, … Experimental Design: Patients with lung adenocarcinoma …

… benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer,
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …

… of patients with ASC who were treated with gefitinib or erlotinib at Zhejiang Cancer Hospital
… However, the treatment efficacy is much lower in patients with squamous lung cancer. In the …

… in survival for patients with stage IV non-small cell lung cancer (… in up to 16% of patients with
stage III lung cancer [6]. Despite modest … Most lung cancer physicians believe that the major …

… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …

… the status of erlotinib treatment and EGFR mutation in lung SCC patients. Methods: We
retrospectively enrolled lung cancer patients with SCC histology and history of erlotinib treatment. …

… erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell
lung cancer (… plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. …

… of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However,
there … of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. …

… Study design and patients Using an institutional query system, we identified all patients
with BMs and lung adenocarcinoma who harbored EGFR mutations and were treated at our …